Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank Disease ID
1 Adipocytokine signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
2 Adipocytokine signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
3 Adipocytokine signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
4 African trypanosomiasis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
6 African trypanosomiasis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
7 African trypanosomiasis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
8 African trypanosomiasis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
14 Alcoholic liver disease 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
15 Alcoholic liver disease 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
16 Alcoholic liver disease 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
17 Alcoholic liver disease 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
18 Alcoholic liver disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
19 Alcoholic liver disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
20 Alcoholic liver disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
21 Alcoholic liver disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
22 Allograft rejection 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
23 Allograft rejection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
24 Allograft rejection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
25 Alzheimer disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
26 Alzheimer disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
27 Alzheimer disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
28 Alzheimer disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
29 Amoebiasis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
30 Amoebiasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
31 Amoebiasis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
32 Amoebiasis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
33 Amoebiasis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
34 Amyotrophic lateral sclerosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
35 Amyotrophic lateral sclerosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
36 Antigen processing and presentation 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
37 Antigen processing and presentation 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
38 Apoptosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
39 Apoptosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
40 Asthma 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
41 Asthma 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
42 C-type lectin receptor signaling pathway 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
43 C-type lectin receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
44 C-type lectin receptor signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
45 C-type lectin receptor signaling pathway 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
46 C-type lectin receptor signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
47 C-type lectin receptor signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
48 Chagas disease 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
49 Chagas disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
50 Chagas disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
51 Chagas disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
52 Chagas disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
53 Chemical carcinogenesis - receptor activation 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
54 Chemokine signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
55 Cholinergic synapse 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
56 Complement and coagulation cascades 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
57 Coronavirus disease 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
58 Coronavirus disease 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
59 Coronavirus disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
60 Coronavirus disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
61 Coronavirus disease 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
62 Coronavirus disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
63 Coronavirus disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
64 Coronavirus disease 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
65 Cytokine-cytokine receptor interaction 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
66 Cytokine-cytokine receptor interaction 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
67 Cytokine-cytokine receptor interaction 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
68 Cytokine-cytokine receptor interaction 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
69 Cytokine-cytokine receptor interaction 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
70 Cytokine-cytokine receptor interaction 💬
[1] IL1RL2 💬 Spesolimab 💬 Spesolimab [5] 37, 96, 97, 160, 269 💬
71 Cytokine-cytokine receptor interaction 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
72 Cytokine-cytokine receptor interaction 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
73 Cytokine-cytokine receptor interaction 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
74 Cytosolic DNA-sensing pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
75 Cytosolic DNA-sensing pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
76 Dilated cardiomyopathy 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
77 Dilated cardiomyopathy 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
78 Efferocytosis 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
79 Epstein-Barr virus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
80 Epstein-Barr virus infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
81 Epstein-Barr virus infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
82 Epstein-Barr virus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
83 Fc epsilon RI signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
84 Fc epsilon RI signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
85 Fluid shear stress and atherosclerosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
86 Fluid shear stress and atherosclerosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
87 Fluid shear stress and atherosclerosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
88 Fluid shear stress and atherosclerosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
89 Graft-versus-host disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
90 Graft-versus-host disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
91 Graft-versus-host disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
92 Graft-versus-host disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
93 Growth hormone synthesis, secretion and action 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
94 Hematopoietic cell lineage 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
95 Hematopoietic cell lineage 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
96 Hematopoietic cell lineage 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
97 Hematopoietic cell lineage 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
98 Hepatitis B 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
99 Hepatitis B 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
100 Hepatitis B 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
101 Hepatitis B 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
102 Hepatitis C 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
103 Hepatitis C 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
104 Hepatitis C 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
105 Hepatitis C 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
106 Herpes simplex virus 1 infection 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
107 Herpes simplex virus 1 infection 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
108 Herpes simplex virus 1 infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
109 Herpes simplex virus 1 infection 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
110 Herpes simplex virus 1 infection 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
111 Herpes simplex virus 1 infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
112 Herpes simplex virus 1 infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
113 Herpes simplex virus 1 infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
114 Hormone signaling 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
115 Human cytomegalovirus infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
116 Human cytomegalovirus infection 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
117 Human cytomegalovirus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
118 Human cytomegalovirus infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
119 Human cytomegalovirus infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
120 Human immunodeficiency virus 1 infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
121 Human immunodeficiency virus 1 infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
122 Human papillomavirus infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
123 Human papillomavirus infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
124 Human papillomavirus infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
125 Human papillomavirus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
126 Human T-cell leukemia virus 1 infection 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
127 Human T-cell leukemia virus 1 infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
128 Human T-cell leukemia virus 1 infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
129 Hypertrophic cardiomyopathy 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
130 Hypertrophic cardiomyopathy 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
131 IL-17 signaling pathway 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
132 IL-17 signaling pathway 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
133 IL-17 signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
134 IL-17 signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
135 IL-17 signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
136 IL-17 signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
137 Inflammatory bowel disease 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
138 Inflammatory bowel disease 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
139 Inflammatory bowel disease 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
140 Inflammatory bowel disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
141 Inflammatory bowel disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
142 Inflammatory bowel disease 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
143 Inflammatory bowel disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
144 Inflammatory bowel disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
145 Inflammatory mediator regulation of TRP channels 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
146 Inflammatory mediator regulation of TRP channels 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
147 Influenza A 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
148 Influenza A 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
149 Influenza A 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
150 Influenza A 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
151 Influenza A 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
152 Influenza A 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
153 Influenza A 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
154 Insulin resistance 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
155 Insulin resistance 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
156 JAK-STAT signaling pathway 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
157 JAK-STAT signaling pathway 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
158 JAK-STAT signaling pathway 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
159 JAK-STAT signaling pathway 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
160 Kaposi sarcoma-associated herpesvirus infection 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
161 Kaposi sarcoma-associated herpesvirus infection 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
162 Legionellosis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
163 Legionellosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
164 Legionellosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
165 Legionellosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
166 Legionellosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
167 Leishmaniasis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
168 Leishmaniasis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
169 Leishmaniasis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
170 Leishmaniasis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
171 Leishmaniasis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
172 Leishmaniasis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
173 Lipid and atherosclerosis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
174 Lipid and atherosclerosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
175 Lipid and atherosclerosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
176 Lipid and atherosclerosis 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
177 Lipid and atherosclerosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
178 Lipid and atherosclerosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
179 Malaria 💬
[1] IL12A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
180 Malaria 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
181 Malaria 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
182 Malaria 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
183 Malaria 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
184 MAPK signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
185 MAPK signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
186 MAPK signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
187 MAPK signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
188 Measles 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
189 Measles 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
190 Measles 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
191 Measles 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
192 Measles 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
193 mTOR signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
194 mTOR signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
195 Natural killer cell mediated cytotoxicity 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
196 Natural killer cell mediated cytotoxicity 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
197 Necroptosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
198 Necroptosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
199 Necroptosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
200 Necroptosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
201 Necroptosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
202 Necroptosis 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
203 Neuroactive ligand-receptor interaction 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
204 Neuroactive ligand-receptor interaction 💬
[1] NR3C1 💬 Prednisolone 💬 Prednisolone [48]  3 , 11, 13, 14, 18, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 57, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 111, 113, 145, 162, 222, 223, 251, 269, 271, 296, 299, 300 💬
205 Neuroactive ligand-receptor interaction 💬
[1] NR3C1 💬 Prednisone 💬 Prednisone [58]  2 , 11, 13, 14, 18, 19, 26, 28, 35, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 53, 60, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 90, 93, 95, 96, 97, 113, 127, 145, 162, 164, 205, 222, 223, 224, 228, 251, 269, 283, 284, 285, 288, 299, 300, 303, 307, 331 💬
206 Neutrophil extracellular trap formation 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
207 NF-kappa B signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
208 NF-kappa B signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
209 NF-kappa B signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
210 NF-kappa B signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
211 NOD-like receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
212 NOD-like receptor signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
213 NOD-like receptor signaling pathway 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
214 NOD-like receptor signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
215 NOD-like receptor signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
216 NOD-like receptor signaling pathway 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
217 Non-alcoholic fatty liver disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
218 Non-alcoholic fatty liver disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
219 Non-alcoholic fatty liver disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
220 Non-alcoholic fatty liver disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
221 Osteoclast differentiation 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
222 Osteoclast differentiation 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
223 Osteoclast differentiation 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
224 Osteoclast differentiation 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
225 Osteoclast differentiation 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
226 Osteoclast differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
227 Pancreatic cancer 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
228 Pathogenic Escherichia coli infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
229 Pathogenic Escherichia coli infection 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
230 Pathogenic Escherichia coli infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
231 Pathogenic Escherichia coli infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
232 Pathways in cancer 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
233 Pathways in cancer 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
234 Pathways in cancer 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
235 Pathways of neurodegeneration - multiple diseases 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
236 Pathways of neurodegeneration - multiple diseases 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
237 Pathways of neurodegeneration - multiple diseases 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
238 Pathways of neurodegeneration - multiple diseases 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
239 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
240 Pertussis 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
241 Pertussis 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
242 Pertussis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
243 Pertussis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
244 Pertussis 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
245 Pertussis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
246 Pertussis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
247 PI3K-Akt signaling pathway 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
248 Prion disease 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
249 Prion disease 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
250 Prion disease 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
251 Prion disease 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
252 Prion disease 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
253 Prolactin signaling pathway 💬
[1] JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
254 Proteoglycans in cancer 💬
[1] IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
255 Proteoglycans in cancer 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
256 Proteoglycans in cancer 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
257 Regulation of actin cytoskeleton 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
258 Rheumatoid arthritis 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
259 Rheumatoid arthritis 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
260 Rheumatoid arthritis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
261 Rheumatoid arthritis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
262 Rheumatoid arthritis 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
263 Rheumatoid arthritis 💬
[1] IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
264 Rheumatoid arthritis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
265 Rheumatoid arthritis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
266 RIG-I-like receptor signaling pathway 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
267 RIG-I-like receptor signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
268 RIG-I-like receptor signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
269 Salmonella infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
270 Salmonella infection 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
271 Salmonella infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
272 Salmonella infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
273 Shigellosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
274 Shigellosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
275 Shigellosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
276 Shigellosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
277 Signaling pathways regulating pluripotency of stem cells 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
278 Sphingolipid signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
279 Sphingolipid signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
280 Staphylococcus aureus infection 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
281 Systemic lupus erythematosus 💬
[1] C5 💬 Vilobelimab 💬 Vilobelimab [3] 43, 44, 269 💬
282 Systemic lupus erythematosus 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
283 Systemic lupus erythematosus 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
284 T cell receptor signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
285 T cell receptor signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
286 TGF-beta signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
287 TGF-beta signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
288 Th1 and Th2 cell differentiation 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
289 Th1 and Th2 cell differentiation 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
290 Th1 and Th2 cell differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
291 Th17 cell differentiation 💬
[1] IL17A 💬 Ixekizumab 💬 Ixekizumab [8] 36, 37, 46, 107, 160, 162, 269, 271 💬
292 Th17 cell differentiation 💬
[1] IL17A 💬 Secukinumab 💬 Secukinumab [9] 13, 37, 40, 41, 46, 107, 160, 269, 271 💬
293 Th17 cell differentiation 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
294 Th17 cell differentiation 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
295 Th17 cell differentiation 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
296 Th17 cell differentiation 💬
[1] IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
297 Th17 cell differentiation 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
298 Th17 cell differentiation 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
299 TNF signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
300 TNF signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
301 TNF signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
302 TNF signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
303 Toll-like receptor signaling pathway 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
304 Toll-like receptor signaling pathway 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
305 Toll-like receptor signaling pathway 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
306 Toll-like receptor signaling pathway 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
307 Toll-like receptor signaling pathway 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
308 Toll-like receptor signaling pathway 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
309 Toll-like receptor signaling pathway 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
310 Toxoplasmosis 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
311 Toxoplasmosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
312 Toxoplasmosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
313 Toxoplasmosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
314 Toxoplasmosis 💬
[1] TYK2 💬 Deucravacitinib 💬 Deucravacitinib [10] 36, 37, 40, 49, 53, 84, 96, 97, 160, 269 💬
315 Tuberculosis 💬
[3] IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
316 Tuberculosis 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
317 Tuberculosis 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
318 Tuberculosis 💬
[1] IL23A 💬 Guselkumab 💬 Guselkumab [7] 37, 41, 51, 96, 97, 161, 269 💬
319 Tuberculosis 💬
[2] JAK1, JAK2 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
320 Tuberculosis 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
321 Tuberculosis 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
322 Type I diabetes mellitus 💬
[2] IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab [17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
323 Type I diabetes mellitus 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
324 Type I diabetes mellitus 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
325 Type I diabetes mellitus 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
326 Type I diabetes mellitus 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
327 Type II diabetes mellitus 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
328 Type II diabetes mellitus 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
329 Viral carcinogenesis 💬
[1] JAK1 💬 Baricitinib 💬 Baricitinib [24]  2 , 13, 40, 41, 46, 49, 50, 51, 53, 54, 56, 63, 65, 84, 93, 107, 135, 162, 265, 268, 269, 300, 325, 345 💬
330 Viral protein interaction with cytokine and cytokine receptor 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
331 Viral protein interaction with cytokine and cytokine receptor 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬
332 Yersinia infection 💬
[1] IL1B 💬 Canakinumab 💬 Canakinumab [11] 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
333 Yersinia infection 💬
[1] IL1B 💬 Gevokizumab 💬 Gevokizumab [4] 41, 50, 56, 269 💬
334 Yersinia infection 💬
[1] TNF 💬 Adalimumab 💬 Adalimumab [22] 19, 37, 38, 40, 41, 46, 55, 56, 84, 90, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
335 Yersinia infection 💬
[1] TNF 💬 Infliximab 💬 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 223, 269, 270, 271 💬